Andrew Morris

Andrew Morris

Auto-generated profile, based on publicly available information

Andrew Morris

Swansea University Medical School, Swansea University

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2019 in AAPS PharmSciTech
Verified
Journal Article
Closed access
PDF file
RNRajesh Sreedharan Nair
Rajesh Sreedharan Nair
AMAndrew Morris
Andrew Morris
Nashiru BillaNashiru Billa
Nashiru Billa
CLChee-Onn Leong
Chee-Onn Leong


1 March 2005 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
PDF file
RCR.P. Chilcott
R.P. Chilcott
NBN. Barai
N. Barai
ABA.E. Beezer
A.E. Beezer
SBS.I. Brain
S.I. Brain
MBM.B. Brown
M.B. Brown
JHJ. Hadgraft
J. Hadgraft

15 December 2020 in Pharmaceutical Development and Technology
Verified
Journal Article
Closed access
RNRajesh Sreedharan Nair
Rajesh Sreedharan Nair
Nashiru BillaNashiru Billa
Nashiru Billa
CLChee-Onn Leong
Chee-Onn Leong
AMAndrew P. Morris
Andrew P. Morris
Tocotrienol (TRF) ethosomes were developed and evaluated in vitro for potential transdermal delivery against melanoma. The optimised TRF ethosomal size ranged between 64.9 ± 2.2 nm to 79.6 ± 3.9 nm and zeta potential (ZP) between -53.3 mV to -62.0 ± 2.6 mV. Characterisation of the ethosomes by ATR-FTIR indicated the successful formation of TRF-ethosomes. Scanning electron microscopy (SEM) images demonstrated the spherical shape of ethosomes, and the entrapment efficiencies of all the formulations were above 66%. In vitro permeation studies using full-thickness human skin showed that the permeation of gamma-T3 from the TRF ethosomal formulations was significantly higher (P < 0.05) than from the control. The cumulative amount of gamma-T3 permeated from TRF ethosome after 48 hours was 1.03 ± 0.24 µg cm−2 with a flux of 0.03 ± 0.01 µg cm−2 h−1. Furthermore, the flux of gamma-T3 across the Strat-M ® and the epidermal membrane was significantly higher than that across full-thickness human skin (p < 0.05). In vitro cytotoxicity studies on HaCat cells showed significantly higher cell viability than the pure drug solution (p < 0.05). The enhanced skin permeation and high cell viability associated with this formulation suggest a promising carrier for the transdermal delivery. Graphical Abstract

17 August 2017 in Journal of Biomaterials Science, Polymer Edition
Verified
Journal Article
Closed access
YBYamina Boukari
Yamina Boukari
OQOmar Qutachi
Omar Qutachi
DSDavid J. Scurr
David J. Scurr
AMAndrew P. Morris
Andrew P. Morris
SDStephen W. Doughty
Stephen W. Doughty
Nashiru BillaNashiru Billa
Nashiru Billa
The development of patient-friendly alternatives to bone-graft procedures is the driving force for new frontiers in bone tissue engineering. Poly ( dl -lactic-co-glycolic acid) (PLGA) and chitosan are well-studied and easy-to-process polymers from which scaffolds can be fabricated. In this study, a novel dual-application scaffold system was formulated from porous PLGA and protein-loaded PLGA/chitosan microspheres. Physicochemical and in vitro protein release attributes were established. The therapeutic relevance, cytocompatibility with primary human mesenchymal stem cells (hMSCs) and osteogenic properties were tested. There was a significant reduction in burst release from the composite PLGA/chitosan microspheres compared with PLGA alone. Scaffolds sintered from porous microspheres at 37 °C were significantly stronger than the PLGA control, with compressive strengths of 0.846 ± 0.272 MPa and 0.406 ± 0.265 MPa, respectively (p < 0.05). The formulation also sintered at 37 °C following injection through a needle, demonstrating its injectable potential. The scaffolds demonstrated cytocompatibility, with increased cell numbers observed over an 8-day study period. Von Kossa and immunostaining of the hMSC-scaffolds confirmed their osteogenic potential with the ability to sinter at 37 °C in situ.

1 February 2009 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
AMAndrew P. Morris
Andrew P. Morris
KBKeith R. Brain
Keith R. Brain
Charles HeardCharles Heard
Charles Heard